MRNA vs ROIV
Moderna and Roivant Sciences Ltd., both Healthcare
Moderna is the larger company at $25B against $23B. Over the past year ROIV returned +218% against +93% for MRNA. Ryufin's sector-relative Smart Score puts MRNA ahead, 9/10 against 7/10.
| Figure | MRNA | ROIV |
|---|---|---|
| Last close | $62.96 | $36.77 |
| Market cap | $25B | $23B |
| 1-year return | +93% | +218% |
| 5-year return | -81% | +272% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 81% of the disclosed total.
Roivant Sciences Ltd.
Revenue of $3M in Q4 2025, net income $303M.
Open these two in the interactive comparison to add more names, change the period or read the correlation.